Cover Image
市場調查報告書

T淋巴球活性化抗原CD80:開發中產品分析

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 516018
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
T淋巴球活性化抗原CD80:開發中產品分析 T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 76 Pages
簡介

本報告提供以T淋巴球活性化抗原CD80為標的之治療藥開發相關資訊,提供開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

T淋巴球活性化抗原CD80;概要

T淋巴球活性化抗原CD80;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 3SBio Inc
  • BioAtla LLC
  • Bristol-Myers Squibb Company
  • KAHR medical Ltd
  • MediGene AG
  • MedImmune LLC
  • Momenta Pharmaceuticals Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

目錄
Product Code: GMDHC0833TDB

Summary

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H1 2017, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, Dermatomyositis, Giant Cell Arteritis, Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener Polyangiitis), Hepatocellular Carcinoma, Juvenile Rheumatoid Arthritis, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyositis/Idiopathic Inflammatory Myopathy, Primary Biliary Cirrhosis, Psoriasis, Psoriatic Arthritis, Sicca Syndrome (Sjogren), Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Takayasu Arteritis, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes), Uveitis and Vitiligo.

Furthermore, this report also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
  • The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Overview
    • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • BioAtla LLC
    • Bristol-Myers Squibb Company
    • KAHR medical Ltd
    • MediGene AG
    • MedImmune LLC
    • Momenta Pharmaceuticals Inc
  • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUE-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAHR-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KN-019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-5265 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RhuDex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Dormant Products
  • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Discontinued Products
  • T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 13, 2017: Bristol-Myers Squibb's Orencia Rejects For Use Within NHS Scotland
      • Nov 14, 2016: Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
      • Nov 10, 2016: Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
      • Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)
      • Sep 06, 2016: European Commission Approves Bristol-Myers Squibb's ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate
      • Jul 25, 2016: CHMP Issues Positive Opinion for ORENCIA (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU
      • Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Orencia
      • Jul 20, 2016: Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA (abatacept) ClickJect, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis
      • Jun 08, 2016: Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016)
      • May 25, 2016: Launch of Orencia SC 125 mg Auto-injector 1 mL for Treatment of Rheumatoid Arthritis
      • Feb 26, 2016: Manufacturing and Marketing Approval of Orencia SC 125 mg Auto-injector 1 mL for Rheumatoid Arthritis Treatment
      • Jan 26, 2016: NICE issues final guidance recommending abatacept for rheumatoid arthritis
      • Dec 18, 2015: Initiating AVERT-2 Study in Japan, an International Phase IIIb Clinical Study of Orencia in Previously Untreated Rheumatoid Arthritis Patients
      • Nov 05, 2015: Bristol-Myers Squibb to Present Data from 24 Abstracts in Immunoscience at the American College of Rheumatology 2015 Congress
      • Jun 09, 2015: New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of Poor Prognosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by 3SBio Inc, H1 2017
  • Pipeline by BioAtla LLC, H1 2017
  • Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pipeline by KAHR medical Ltd, H1 2017
  • Pipeline by MediGene AG, H1 2017
  • Pipeline by MedImmune LLC, H1 2017
  • Pipeline by Momenta Pharmaceuticals Inc, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top